Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Buys $169,100.80 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc acquired 6,005 shares of the firm’s stock in a transaction on Tuesday, March 31st. The stock was bought at an average price of $28.16 per share, with a total value of $169,100.80. Following the purchase, the insider directly owned 146,657 shares of the company’s stock, valued at $4,129,861.12. This represents a 4.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total transaction of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total transaction of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total transaction of $23,629.68.
• On Monday, March 30th, Millennium Management Llc acquired 9,533 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total transaction of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total transaction of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc bought 6,175 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $34.49 per share, with a total value of $212,975.75.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total transaction of $246,231.92.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ:SNSE traded up $0.61 on Friday, reaching $20.43. The company’s stock had a trading volume of 40,084 shares, compared to its average volume of 223,112. The stock’s 50-day moving average is $29.11 and its two-hundred day moving average is $17.85. Sensei Biotherapeutics, Inc. has a 52-week low of $5.25 and a 52-week high of $36.76. The stock has a market capitalization of $27.40 million, a P/E ratio of -1.23 and a beta of -0.18.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). Equities analysts forecast that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SNSE. Leerink Partners began coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price for the company. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the period. Renaissance Technologies LLC owned approximately 2.39% of Sensei Biotherapeutics worth $1,010,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.50% of the company’s stock.

More Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.